XML 76 R64.htm IDEA: XBRL DOCUMENT v3.25.3
Debt - Liability for Sale of Future Royalties Narrative (Details)
$ in Thousands
 1 Months Ended 9 Months Ended
Oct. 18, 2023
USD ($)
Option
Jul. 17, 2020
USD ($)
Jun. 30, 2024
USD ($)
Sep. 30, 2025
USD ($)
tranche
Sep. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
Assigned royalty payments            
Cash consideration received from A&R Royalty Purchase Agreement         $ 241,792  
Assigned royalty payment, retained percentage   57.067%        
Remaining potential milestones that can be achieved           $ 150,000
Effective interest rate of the liability component       9.30%    
Aggregate Royalty Purchase Agreements | Royalty Pharma            
Assigned royalty payments            
Aggregate percentage of royalty rights sold 80.9777%          
Original Royalty Purchase Agreement            
Assigned royalty payments            
Assigned royalty payment, percentage   42.933%        
Cash consideration received from A&R Royalty Purchase Agreement   $ 650,000        
Royalty purchase agreement termination period once there are no further royalty payment obligations   60 days        
Assigned Royalty Cap per terms of the royalty purchase agreement $ 1,300,000 $ 1,300,000        
A&R Royalty Purchase Agreement            
Assigned royalty payments            
Cash consideration received from A&R Royalty Purchase Agreement $ 1,000,000   $ 241,800      
Assigned royalty payment, retained percentage       9.51%    
Royalty purchase agreement termination period once there are no further royalty payment obligations 60 days     60 days    
Retained Royalty Rights percentage sold 38.0447%          
Aggregate percentage of royalty rights sold       90.49%    
Percentage of total royalty payable after threshold royalties received 66.6667%          
Additional cash consideration $ 500,000          
Number of put options held by the company | Option 5          
Maximum number of put options which can be exercised before Royalty Pharma can exercise a call option | Option 2          
Maximum percentage of remaining retained royalty rights that are available upon exercise of call option 50.00%          
Percentage of maximum royalty payable until assigned royalty rights       83.33%    
Fair value of liability for sale of future royalties. $ 1,809,900          
Loss on extinguishment of debt $ 44,900          
Effective interest rate of the liability component 10.80%   9.90%      
Liability recognized for sale of future royalties.     $ 241,800      
Adjusted percentage of retained royalty rights after the 2020 Assigned Royalty Cap is met       16.67%    
A&R Royalty Purchase Agreement | Maximum            
Assigned royalty payments            
Number of tranches to sell retained royalty | tranche       3    
A&R Royalty Purchase Agreement | Royalty Pharma            
Assigned royalty payments            
Percentage of maximum royalty payable until assigned royalty rights 90.4888%          
Percentage of maximum royalty payable thereafter assigned royalty rights 83.3333%          
A&R Royalty Purchase Agreement | Royalty Pharma            
Assigned royalty payments            
Assigned Royalty Cap per terms of the royalty purchase agreement       $ 1,300,000    
Aggregate upfront cash consideration received for sale of future royalties       $ 1,900,000    
A&R Royalty Purchase Agreement Tranche One            
Assigned royalty payments            
Aggregate percentage of royalty rights sold       3.81%    
Contract price for sale of specified percentage of future royalties       $ 100,000    
Adjusted percentage of retained royalty rights sold after the 2020 Assigned Royalty Cap is met       6.67%    
A&R Royalty Purchase Agreement Tranche Two            
Assigned royalty payments            
Aggregate percentage of royalty rights sold       3.81%    
Contract price for sale of specified percentage of future royalties       $ 100,000    
Adjusted percentage of retained royalty rights sold after the 2020 Assigned Royalty Cap is met       6.67%    
A&R Royalty Purchase Agreement Tranche Three            
Assigned royalty payments            
Aggregate percentage of royalty rights sold       1.90%    
Contract price for sale of specified percentage of future royalties       $ 50,000    
Adjusted percentage of retained royalty rights sold after the 2020 Assigned Royalty Cap is met       3.33%